Lamivudine dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Lamivudine is a thirty year old HIV and hepatitis B pill. Some scientists think old gene fragments waking up in our DNA drive the constant low-level inflammation of ageing, and this drug might block them. The only ageing-type study in people gave it to 12 people with early Alzheimer's. There was no comparison group.
Evidence grade for Lamivudine: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for HIV-1 infection, taken together with other HIV drugs. A separate lower-dose product is approved for long-term hepatitis B. Not approved for ageing, inflammation or diseases that destroy brain cells.
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Brain, memory and mood, Ageing and longevity, Injury, healing and recovery, Immune system and inflammation, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Lamivudine is an HIV and hepatitis B pill that has been used for about thirty years. It blocks a copying enzyme that viruses use. Some scientists think it could also calm the low-level inflammation of ageing. That idea is still being tested.
What people take it for
- Cutting age-linked inflammation.
- Slowing ageing, based on mouse studies.
- Protecting the brain from Alzheimer's.
What studies in people showed
The only ageing-type study in people was a pilot in 12 people with early Alzheimer's. They took 300 mg a day, and there was no comparison group. Safety looked good, and thinking scores held steady. A marker of brain inflammation fell. With 12 people and nothing to compare against, that is a clue, not proof. In old mice, it cut inflammation. In mice bred to age fast, drugs like it helped them live longer. Nobody has tested whether it helps normal mice live longer.
What people report
Reports, not study results
The good
- Most people say it is easy to take, which matches its long medical record.
The bad
- Headache, nausea and tiredness are the most common early complaints.
- If you carry hepatitis B without knowing, stopping the drug can cause a severe flare. Longevity groups rarely talk about this.
Where these come from: Longevity forums and clinic write-ups, as collected on this page. The hepatitis B warning is on the drug's label.
My bottom line
Smart idea, one tiny pilot. If you ever try it, get tested for hepatitis B first. Without that test, I would not start it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Lamivudine has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Memory and thinkingno headcount stated · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Lamivudine, what they expect, and what goes wrong. The full account, including the negative reports, is below.
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. This is an approved medicine. So the missing study in people is for this use, not for the drug. Drug makers paid to test it for what it is approved for. The record on this one is set out below.
- Living longer2 animal or lab studies
- Inflammation1 animal or lab study
31 of the 36 indexed goals have no study of any kind behind Lamivudine
No study in people, animals or cells on this page reports a result for these. That does not prove Lamivudine does nothing for them. It does mean anything you have heard about Lamivudine and one of these did not come from a study cited here.
Show full evidence
What is Lamivudine?
Lamivudine is a thirty year old HIV and hepatitis B pill. Some scientists think old gene fragments waking up in our DNA drive the constant low-level inflammation of ageing, and this drug might block them. The only ageing-type study in people gave it to 12 people with early Alzheimer's. There was no comparison group.
About 40 percent of human DNA is made of old gene fragments that can copy themselves. The main ones are called LINE-1, or jumping genes. Most of the time the body keeps them switched off. With age, that seems to fail. The idea is that when they wake up, they make loose copies of DNA inside the cell. The cell's alarm system mistakes those copies for a virus. That sets off an immune alarm and constant low-level inflammation.
If that is right, a drug that blocks the copying step should stop it. Lamivudine is the obvious choice. It blocks that kind of copying in HIV, and millions of people have taken it for decades.
Two 2019 papers built the case. The first showed these fragments wake up in worn-out cells and set off the immune alarm. It found that giving lamivudine to old mice turned down that alarm and cut inflammation in several body parts. The second used mice missing a gene called SIRT6. Those mice age fast and die young. They build up the loose DNA copies. Drugs like lamivudine made them healthier, helped them live longer, and fully switched off the alarm.
Both are real results. Neither shows normal ageing animals living longer. The first paper measured inflammation in old mice, not survival. The longer life in the second paper was in mice bred to age fast, which is a different claim.
In people, there is one study. It was an early pilot in 12 people with early Alzheimer's disease, taking 300 mg of lamivudine a day. Safety looked good and thinking scores held steady. A marker of brain inflammation in spinal fluid fell. A blood marker linked to Alzheimer's plaques rose. Twelve people, no dummy pill group, and lab markers only.
How does Lamivudine work?
Inside cells, lamivudine turns into a fake DNA building block. When a copying enzyme called reverse transcriptase picks it up, the DNA chain stops growing. In HIV and hepatitis B, that stops the virus copying itself. For ageing, the target is a different copying enzyme, the one made by the LINE-1 jumping genes. The aim is to stop loose DNA copies piling up inside cells and setting off the immune alarm. So the hoped-for benefit is less age-linked inflammation, not a direct fix to how cells age.
What have studies in people found about Lamivudine?
Thirty years of use in HIV and hepatitis B, with a large, well-known safety record. For ageing, one pilot in 12 people with no comparison group, measuring only lab markers.
- Used since the 1990s for HIV and long-term hepatitis B. So the safety picture at these doses is unusually well known for a drug being tried for something new.
- In the Alzheimer's pilot, 12 people took 300 mg a day and knew it. A marker of brain inflammation in spinal fluid fell. A blood marker linked to Alzheimer's plaques rose. Thinking scores were described as stable.
- There was no dummy pill group, so steady thinking over the study cannot be credited to the drug.
- No study in people has measured jumping gene activity, age-linked inflammation, biological age, frailty or lifespan in healthy older people on lamivudine.
What this does not tell you: A 12 person pilot with no comparison group and only lab markers is a test of whether a study can be done. The authors present it that way. Steady thinking in early Alzheimer's over a short time is not a sign of treatment without a group to compare. There is a separate, practical problem. The long safety record comes from people closely watched by specialists for HIV or hepatitis B. Someone taking lamivudine for ageing has none of that. That includes the risk of a severe hepatitis B flare when stopping the drug, if they carry the virus without knowing.
What do people who took Lamivudine report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Most people describe it as easy to take. That matches the medical record. Headache, nausea and tiredness are the most common early complaints.
- Longevity users often take the hepatitis B dose or the HIV dose without knowing which one the mouse work matches. Nobody has worked out a human dose for this use.
- The risk of a hepatitis B flare when stopping gets far too little attention in longevity groups, given how serious it is.
Sources: Longevity forums and clinic write-ups. Uncontrolled self-report, useful for what to watch for, not evidence of effect.
The state of the research
Any old drug used for something new raises two separate questions, and they have different answers. First: does the drug do what it was approved to do? Here, big studies in sick people settle that. Second: does it slow ageing in people? No study has tested that. A strong answer to the first question says nothing about the second. Treating the approved use as part proof that it slows ageing is the biggest mistake in this field.
The jumping gene idea is one of the smartest in ageing science right now. Two separate 2019 papers back it, in the journals Nature and Cell Metabolism. It is worth being exact about what they did and did not show. The Nature paper gave lamivudine to old mice. It measured the immune alarm and inflammation in body tissues, and found both went down. It did not test whether the mice lived longer. The Cell Metabolism paper did find longer lives on drugs like lamivudine. But that was in mice missing the SIRT6 gene, which age very fast. That is not normal ageing. Helping a short-lived mutant mouse live longer is a weaker claim than helping a normal one. The two often get reported as if they were the same.
The Nature paper also has a published correction from its authors. That is a normal part of science, not a retraction. It is listed here because anyone checking the paper will see it and should know what it means.
Nobody has tested whether lamivudine helps normal ageing mice live longer. That is the obvious experiment. Its absence is the honest headline for this drug.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
2 of 5 sources here are studies in people. The rest are not.
- Study in people · done in people240%
- Animal study · done in animals360%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2019 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 229.3 Da
- Half-life
- About 6 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: Roughly 5 to 7 hours in plasma; the active intracellular triphosphate persists considerably longer.
No amino acid sequence is on file for Lamivudine, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2025A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer's disease (ART-AD)
This is the only time the idea has been tried in people, and it was not built to show benefit. 12 people with early Alzheimer disease took 300 mg of lamivudine a day. Everybody knew what they were taking and there was nothing to compare against. Safety looked acceptable and thinking scores held steady. A marker of brain inflammation in the spinal fluid fell. The authors say a proper trial with a dummy group is the next step. One author declares an advisory role with a company in this area.
The only human study in this line of work. Open label, no control group, 12 participants with early Alzheimer disease on 300 mg of lamivudine daily. Reported a favourable safety profile, stable cognitive measures, a reduction in cerebrospinal fluid GFAP (P = 0.03) suggesting reduced neuroinflammation, and an elevation in plasma amyloid beta 42 to 40 ratio (P = 0.009). The authors state the results warrant a larger placebo-controlled trial. One author discloses a scientific advisory role with a retrotransposon-focused company.
- Study in people2023Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
This is the registry record for that pilot, and it adds no result. The study is listed as completed, with 12 people actually enrolled, running from February 2021 to November 2023. The record confirms two things the paper already says: the study was tiny, and nobody in it was assigned by chance to a comparison group.
The ART-AD registration, listed as completed with an actual enrolment of 12, running from February 2021 to November 2023. The registry record confirms the pilot scale and the absence of a randomised comparator.
- Animal study2019L1 drives IFN in senescent cells and promotes age-associated inflammation
In mice and in a dish. This is the paper that started the idea. In worn-out cells, jumping genes woke up and set off an immune alarm through loose DNA copies. Drugs that block the copying stopped it. Giving lamivudine to old mice turned down the alarm and cut inflammation in several body parts. It measured inflammation, not lifespan. The paper has a published author correction, which is not a retraction.
The founding paper. LINE-1 elements become transcriptionally derepressed during cellular senescence and activate a type I interferon response, triggered by cytoplasmic LINE-1 complementary DNA and blocked by LINE-1 reverse transcriptase inhibitors. Treating aged mice with lamivudine downregulated interferon activation and age-associated inflammation in several tissues. Inflammation endpoints, not survival. The paper carries a published author correction in Nature in 2019, which is a correction and not a retraction.
- Animal study2019LINE1 Derepression in Aged Wild-Type and SIRT6-Deficient Mice Drives Inflammation
In mice. Mice missing the SIRT6 gene age fast and die young. They build up loose jumping-gene DNA that sets off an immune alarm. Drugs like lamivudine made these mice healthier, helped them live longer, and fully switched off the alarm. Normal old mice showed the same alarm signs, but nobody tested whether the drug helped them live longer.
The lifespan-shaped result, and it is in a progeroid model. SIRT6-deficient mice, which are severely short lived, accumulate cytoplasmic LINE-1 complementary DNA that triggers a type I interferon response via cGAS. Nucleoside reverse transcriptase inhibitors significantly improved the health and lifespan of these knockout mice and completely rescued the interferon response. The same paper reports elevated LINE-1 transcription, cytoplasmic complementary DNA and type I interferon in normally aged wild-type mice, without a lifespan experiment in those animals.
- Animal study2022Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome
In mice. In mice bred to model Down syndrome, lamivudine fixed problems with learning and memory. It backs the same idea in a different kind of mouse. It is not evidence about ageing in people.
An independent line of rodent evidence for the same mechanism in a different model, reporting rescue of cognitive deficits in a Down syndrome mouse model. Useful as replication of a mechanism in animals, and not evidence about ageing in people.
Common questions
Has Lamivudine been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Lamivudine is a thirty year old HIV and hepatitis B pill. Some scientists think old gene fragments waking up in our DNA drive the constant low-level inflammation of ageing, and this drug might block them. The only ageing-type study in people gave it to 12 people with early Alzheimer's. There was no comparison group.
What is the Lamivudine dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA approved for HIV-1 infection, taken together with other HIV drugs. A separate lower-dose product is approved for long-term hepatitis B. Not approved for ageing, inflammation or diseases that destroy brain cells.
Is Lamivudine FDA-approved?
FDA approved for HIV-1 infection, taken together with other HIV drugs. A separate lower-dose product is approved for long-term hepatitis B. Not approved for ageing, inflammation or diseases that destroy brain cells.
Does lamivudine slow ageing?
There is no evidence in people that it does. In old mice, it cut the immune alarm and age-linked inflammation in several body parts. In mice missing the SIRT6 gene, which age fast, a drug of this type improved health and lifespan. Nobody has tested it in normal ageing mice. The only human study is a 12 person pilot in Alzheimer's with no comparison group.
What is the LINE-1 hypothesis?
LINE-1 elements are old gene fragments that make up a big share of our DNA. Normally they are switched off. With age, that switch fails. When they copy themselves, they leave loose bits of DNA inside the cell. The cell's alarm system reads those as a virus and sets off an immune response. The idea is that this drives the constant low-level inflammation of ageing. A drug that blocks the copying step is the obvious way to test it.
What did the Alzheimer trial find?
The pilot gave 300 mg of lamivudine a day to 12 people with early Alzheimer's. Everyone knew they were on the drug, and there was no dummy pill group. A marker of brain inflammation in spinal fluid fell. A blood marker linked to Alzheimer's plaques rose. Both changes were bigger than chance would likely explain. Thinking scores were described as stable. With 12 people and nothing to compare against, these are early clues for a future study. That is how the authors present them.
Is it safe to take long term?
It has a long safety record in the people it is approved for. That is the strongest safety case any drug on this page can make. The special danger for ageing use is hepatitis B. Someone with hepatitis B who does not know it could start and then stop lamivudine and get a severe flare. That is exactly the person least likely to be watched by a doctor.
Is this the same idea as senolytics?
It is close. Worn-out cells are where scientists first saw the jumping genes wake up and set off the alarm. So both ideas go after the inflammation that worn-out cells give off. Senolytics try to remove those cells. Lamivudine tries to quiet one signal they send.